Bio-Rad Laboratories, Inc. Class A Common Stock vs Ishares Msci Brazil ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Ishares Msci Brazil ETF trades at $36. Which is the better fit depends on your goals.
| BIO | EWZ | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $339.75 | $41.75 |
52-Week Low | $241.71 | $26.52 |
Enterprise Value | $7.85B | — |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
EWZ, the iShares MSCI Brazil ETF, trades at $35.39, down 1.5% for the day, with a bullish technical signal driven by moving averages. The ETF has gained approximately 11% year-to-date, supported by Brazil's monetary easing cycle and commodity strength. Recent news highlights its exposure to Latin America's equity rally and potential from Brazil's $10 billion Eco Invest auction aimed at sustainable technologies.
The outlook for EWZ is positive, with upside from Brazil's rate cuts and commodity markets, but risks include dependence on volatile commodity prices and potential derailment of the easing cycle. The ETF offers a discounted entry to Brazilian equities, yet payout consistency is a concern due to its concentrated holdings in firms like Petrobras and Vale.
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →